Advertisement
Screener

Erasca, Inc. (ERAS) Graph

ERAS Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Operating expenses $47.62M; Net income -$44.08M.
  • 2026-03-31: Operating expenses $187.91M; Net income -$183.44M.
  • 2025-12-31: Operating expenses $32.60M*; Net income -$29.09M*.
  • 2025-09-30: Operating expenses $34.55M; Net income -$30.61M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endOperating expensesNet income
2026-06-30$47.62M-$44.08M
2026-03-31$187.91M-$183.44M
2025-12-31$32.60M*-$29.09M*
2025-09-30$34.55M-$30.61M
2025-06-30$38.13M-$33.88M
2025-03-31$35.63M-$30.97M
2024-09-30$37.24M-$31.20M
2024-06-30$67.78M-$63.20M
2024-03-31$38.85M-$35.02M
2023-09-30$34.66M-$30.36M
2023-06-30$35.97M-$31.78M
2023-03-31$37.02M-$33.20M
2022-09-30$36.96M-$35.49M
2022-06-30$35.91M-$35.61M
2022-03-31$36.51M-$36.46M
2021-09-30$46.04M-$46.07M
2021-06-30$28.18M-$28.21M
2021-03-31$19.61M-$18.02M
2020-09-30$11.16M-$10.61M
2020-06-30$7.28M-$5.49M
2020-03-31(m)-$23.66M

Revenue and expense 6 month

Period endOperating expensesNet income
2026-06-30$235.53M-$227.52M
2025-06-30$73.75M-$64.84M
2024-06-30$106.63M-$98.22M
2023-06-30$73.00M-$64.98M
2022-06-30$72.41M-$72.07M
2021-06-30$47.79M-$46.23M
2020-06-30$31.12M-$29.15M

Revenue and expense 9 month

Period endOperating expensesNet income
2025-09-30$108.30M-$95.45M
2024-09-30$143.88M-$129.42M
2023-09-30$107.65M-$95.34M
2022-09-30$109.37M-$107.56M
2021-09-30$93.83M-$92.30M
2020-09-30$42.28M-$39.76M

Revenue and expense 12 month

Period endOperating expensesIncome taxNet income
2025-12-31$140.91M$0.00-$124.55M
2024-12-31$179.59M$0.00-$161.65M
2023-12-31$141.53M(m)-$125.04M
2022-12-31$247.45M(m)-$242.81M
2021-12-31$124.88M(m)-$122.76M
2020-12-31$109.25M(m)-$101.66M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Veradermics, Inc (MANE)United States$4.839B
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51